Plain-English translation of NCT04511013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a three-drug combination called , , and works better than a two-drug combination of and for treating melanoma that has spread to the brain. Both combinations use medicines that help the immune system fight cancer, but the three-drug treatment also includes two additional medications that target a specific genetic change in melanoma cells. The trial will compare how well each treatment works and how well patients tolerate it.
Melanoma that has spread to the brain is very serious and difficult to treat. Doctors want to know whether adding extra medications to boost the immune system's cancer-fighting power can help patients live longer and keep their cancer from growing.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive one of the two medication combinations. One group takes two pills by mouth daily plus an intravenous infusion once a month; the other group receives intravenous infusions every three weeks for the first four cycles, then every four weeks. You will have regular visits with the study team for exams, blood tests, and brain imaging scans to monitor how the treatment is working and check for side effects. The study continues until your cancer grows, you experience unacceptable side effects, or your doctor decides to stop treatment.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States